INTRODUCTION
In the same manner that clinical phenotypes are associated with genetic variation in genome-wide association studies (GWAS), gene transcript levels can also be associated with genotypes. These studies are called expression genome-wide association studies (eGWAS) when both the genotyping and gene expression quantification are done on a genome-wide scale, through the use of single nucleotide polymorphism (SNP) and gene expression microarrays. Transcript levels are treated as quantitative traits and a genetic locus that associates with a transcript level is called an expression quantitative trait locus (eQTL). eQTLs that occur near the physical genomic location of the gene are known as cis-eQTLs, whereas associations occurring far from the gene or on different chromosomes are referred to as trans-eQTLs. SNPs that are associated with transcript levels are commonly referred to as expression SNPs (eSNPs). The cis-eSNPs, versus trans-eSNPs, are generally stronger and easier to replicate, and may be explained by direct regulation of adjacent gene expression. Here, we highlight some recent eGWAS that illuminated genes involved in atherosclerotic coronary artery disease (CAD). RNAseq is starting to be used instead of expression microarrays, with coverage for genes and noncoding RNAs not present on the arrays, and this data can be similarly used for eQTL studies [1] .
EXPRESSION STUDIES PROVIDE MECHANISTIC INSIGHT INTO CORONARY ARTERY DISEASE-ASSOCIATED REGIONS
A large GWAS identified common genetic variants in an intergenic region located on 1p13.3 that are associated with CAD [2] . Like many GWAS results, the noncoding nature of these variants made determining the mechanism of the association less straightforward than if it were a variant within a coding region of a gene. There are two plausible explanations for an intergenic GWAS finding: the GWAS identified variant is in linkage disequilibrium (often coinherited) with a functional protein coding variant (including those causing alternative splicing); or the identified variant, or a variant in linkage disequilibrium with the identified variant, functions by regulating the expression of a nearby gene. This gene regulation may be due to altering a binding site for a transcription factor or one of the various chromatin-remodeling complexes, thereby altering transcription levels. Thus, eGWAS can be used to determine genetic variants that regulate gene expression, and, if these same variants are associated with the clinical phenotype, then a causative link can be implied: DNA variant ! gene expression change ! disease susceptibility. This type of evidence is much stronger than the mere association between DNA variant and disease susceptibility, and leads to mechanistic insight.
In order to gain insight into the CAD association on chromosome 1p13.3, Schadt et al. [3] obtained SNP genotypes and profiled gene expression from 400 human liver samples. This led to the identification of strong associations between expression levels of a set of genes located within 120 kb of the best-associated CAD SNP on chromosome 1p13.3. CELSR2 and PSRC1 were the genes closest to the CAD SNP, but SORT1 expression was best associated with the CAD SNP [3] . The more common allele (major allele) of the CAD SNP is associated with a greater risk for CAD and lower expression of SORT1 and CELSR2. Using eQTL and low density lipoprotein-cholesterol (LDL-C) data from inbred mouse strains, Schadt et al. [3] were able to rule out PSRC1 as a candidate gene, as only SORT1 and CELSR2 levels were inversely correlated with LDL-C levels. This strongly suggested that PSRC1 was not the causative gene. Work done by Musunuru et al. [4 && ] went on to show that overexpression of SORT1 decreased LDL-C, whereas SORT1 knockdown increased LDL-C, and these changes were mediated via alteration of very low-density lipoprotein (VLDL) secretion from the liver. They also identified the causal genetic variant, rs12740374, that regulates SORT1 expression by sequentially testing the nearby SNPs and observing their effects on gene expression in a reporter gene transfection assay. The minor allele of rs12740374 creates a binding site for the C/EBP transcription factor that increases hepatic expression of SORT1. It must be noted, however, that a study by Kjolby et al. [5] showed an opposite effect of SORT1 expression with LDL-C levels in Ldlr À/À and Sort À/À mice, with SORT1 levels seemingly increasing LDL-C levels. However, the directionality of the LDL-C and SORT1 levels in the Musunuru et al. study is consistent with the findings of Linsel-Nitschke et al. [6] (albeit the latter suggests a role in LDL-C uptake due to SORT1 rather than hepatic VLDL secretion), human genetic associations, and eGWAS experiments. A commentary by Alan Tall and Ding Ai [7] addresses in depth the potential reasons for the differences in these findings. We performed a bioinformatic lookup study of SORT1 eQTLs in publicly available monocyte gene expression data, and we were not able to find a significant SORT1 eQTL for the CADassociated SNP, demonstrating the hepatic tissue specificity for this eQTL. Together, these studies elegantly show how a common variant found in GWAS studies can mechanistically affect gene expression and alter a disease phenotype through a previously unknown component of low-density lipoprotein (LDL) processing and secretion.
The risk locus on chromosome 1p13.3 affects a traditional risk factor, plasma LDL levels. Gene expression studies also potentially offer guidance to explaining risk loci that do not correlate with known CAD risk factors. A recent meta-analysis of more than 100 000 samples found 13 new susceptibility loci for CAD [8 && ]. Of these 13 new loci, three of the loci, on chromosomes 6q23.2, 17p11.2, and 17q21.32, were not associated with traditional
KEY POINTS
Genome-wide expression studies have greatly aided the understanding and elucidation of the genetic effects on clinical traits such as coronary artery disease.
Expression quantitative trait loci in a diverse set of tissues will be necessary to capture all the genetic effects on gene expression.
The utility and power of expression single nucleotide polymorphisms to localize genes of interest in coronary artery disease has been demonstrated and will be of increasing importance in future studies. risk factors, but contained SNPs that upon a bioinformatic lookup had previously been shown to be associated with the expression of nearby genes in liver, omental fat, subcutaneous fat, monocytes, or blood [9 & ]. TCF21 gene expression in liver and omental fat correlated positively with the CAD risk allele on chromosome 6q23.2. Phosphatidylethanolamine N-methyltransferase (PEMT) and RASD1 expression in monocytes was negatively and positively correlated, respectively, with the CAD risk allele on chromosome 17p11.2. PEMT encodes for phosphatidyl ethanolamine methyltransferase, an enzyme that is responsible for part of the hepatic secretion of phosphatidylcholine, a major and essential component of VLDL. It was recently shown that mice deficient in PEMT have decreased plasma cholesterol and triglycerides on the APOE null background [10] . Interestingly, no hepatic eQTL for PEMT was found in multiple eGWAS studies, nor does the risk allele at this locus associate with LDL levels, potentially suggesting an alternate pathway of action. UBE2Z expression in blood was positively correlated with the CAD risk allele on chromosome 17q21.32.
A GWAS study using a multiethnic cohort identified five novel CAD loci, and, of these, two eQTLs were characterized [11 && ]. First, a CAD-associated SNP was located within an intron in the LIPA gene, encoding the lysosomal acid lipase, and a bioinformatic lookup revealed that this same SNP was the strongest eSNP associated with LIPA mRNA levels in circulating monocytes and liver [12] . As lysosomal acid lipase plays a role in the hydrolysis of cholesterol ester stored in lipid droplets of foam cells [13] , this eSNP may provide a direct mechanistic link between macrophage cholesterol metabolism and CAD. Second, a CAD-associated SNP located 117 kb downstream of the PDGFD gene [11 && ] was found to be a strong eQTL for PDGFD expression in aortic media, aortic adventitia, and mammary artery [14] . The CAD risk allele was positively correlated with PDGFD expression in only these three tissues, but not in liver, whole blood, or circulating monocytes. Despite these associations, much work is still needed to elucidate the mechanism of how these genes affect atherosclerosis.
This eQTL for PDGFD expression was characterized in a tissue-specific manner in arterial tissue. The tissue specificity of the correlation offers guidance on what tissues to target in follow-up studies and potentially provides a clue to the role of the particular tissue in disease. However, because not every conceivable tissue can be analyzed by genome-wide expression studies, the presence or absence of a QTL in a tissue is not fully informative. To understand the dynamics of sample size effects and tissue specificity in eQTLs, Dorbin et al. [15 & ] performed an in-silico analysis using expression data from human liver, subcutaneous fat, and omental fat. They found that approximately 90% of cis-eQTLs that are identified in a small population are replicated in a larger sample set, showing the low extent of false positive cis-eQTLs. However, larger sample size studies can identify additional and weaker cis-eQTLs than smaller studies, showing that small studies tend to have high levels of false negative findings. Although it is advantageous to start with a large sample size with more power to detect cis-eQTLs, it still may be worthwhile to obtain expression data in tissues not previously studied even if the sample size is modest, as the determined cis-eQTLs are likely to be real and tissue specificity may be important for the discovery of some eQTLs. Despite valid evidence for the occurrence of tissuespecific eQTLs, the claim of tissue specificity must be evaluated with caution, as small sample sizes with high false negative rates will underestimate the cross-tissue nature of most eQTLs. The eQTL found for PDGFD is an example in which a novel eQTL was found in a tissue that was not previously characterized. However, the lack of an eQTL at a GWAS locus in a particular tissue does not preclude it from having a role in a phenotype, as Dorbin et al. demonstrate that, with larger sample sizes, many originally identified tissue-specific eQTLs are found really to be cross-tissue eQTLs. A possible explanation for this is that replication follows simple scaling laws; more power is required to detect an eQTL in an alternate tissue. Another possibility for some eQTLs is that the genotypic effects on transcript levels could be genuinely stronger in specific tissues. For instance, the transcription of a gene may be more dependent on a particular enhancer element in the liver versus the monocyte. The implication of this is that, at small sample sizes, an eQTL at a CAD risk locus found in one tissue but not in another tissue does not necessarily eliminate the tissue lacking an eQTL as possibly responsible for the correlation between genotype and disease. Nonetheless, the effect size of an eQTL could be informative for its physiological importance. As atherosclerosis is a disease involving many tissues, such as circulating monocytes, hepatocytes, smooth muscle cells, and endothelial cells, cataloging the genetics of gene expression in as many tissues as possible would greatly facilitate a better understanding of the disease.
In one of the largest eGWAS studies published with 1490 samples, Zeller et al. [12] tried to assess whether circulating monocyte gene expression was informative for a set of clinical phenotypes.
Using published GWAS results for lipids, BMI, and blood pressure, they found that most identified GWAS loci for these phenotypes had no nearby genes expressed in monocytes. They concluded that monocyte gene expression plays no role in these traits. However, this study was informative for the chromosome 9p21 CAD risk locus, the strongest CAD risk locus identified in many GWAS, which overlaps with a long noncoding RNA, and is adjacent to two cyclin dependent kinase genes, CDKN2B and CDKN2A [12] . The eSNPs at this locus that associate with CDKN2B expression in monocytes are not the same SNPs that associate with CAD risk [12] . This is consistent with findings from other large studies in which the CAD associated SNPs also did not correlate with monocyte CDKN2B expression [16, 17] , although others have found a correlation in peripheral blood T cells [18] and whole blood [19] . Although monocytes may not be the relevant tissue for the CAD phenotype, this data suggests that the CAD risk alleles mediate disease susceptibility by a mechanism not dependent upon CDKN2B expression in monocytes. Harismendy et al. [20] suggest that the CAD associated SNPs at 9p21 fall within STAT1-binding sites in an enhancer that controls expression of the noncoding RNA via interferon gamma signaling in vascular endothelial cells. These 9p21 gene expression studies are very controversial and the subject of much ongoing research.
CONCLUSION
Expression genome-wide association studies provide complementary evidence to genome-wide association studies. As more CAD associated loci are discovered via GWAS, genome-wide assays of gene expression and the identification of eQTLs/eSNPs will be increasingly important in helping to determine relevant tissues and to prioritize gene targets for follow-up studies.
